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Abstract 
Background: Nuclear phosphoinositides perform the function of cofactors in different nuclear 
processes, including DNA repair and regulation of transcription, with a pathological relevance. 
Indeed, their imbalance can lead to chronic inflammatory diseases, cancer and degenerative 
syndromes. Nuclear inositide signalling pathways, and particularly those regulated by 
Phosphoinositide-specific phospholipase C β1 (PI-PLCβ1), are associated with cell proliferation and 
differentiation, where they can be differentially modulated according to the biological system 
(myogenic, osteogenic, adipogenic or hematopoietic). Myelodysplastic syndromes (MDS) are a 
heterogeneous spectrum of chronic myeloid hemopathies with associated symptomatic 
cytopenias and substantial potential for evolution to acute myeloid leukemia (AML). MDS patients 
are currently treated with two main approaches, epigenetic and immunomodulatory. Azacitidine is 
an epigenetic drug that has much more efficacy in hematologic malignancies than in solid ones. 
Lenalidomide has a specific pro-apoptotic and anti-proliferative effect on MDS cells, above all in 
cell clones bearing a deletion of the long arm of the chromosome 5 [del(5q)]. Moreover, it is able 
to suppress the production of pro-inflammatory cytokines and increase the activation of T and NK 
cells, inducing an immune response. As Azacitidine and Lenalidomide alone can show adverse 
effects or patients can be refractory, an experimental current approach is the combination of the 
two drugs. Clinically, this combination therapy is promising, while its molecular effect, especially in 
terms of gene mutations or mircroRNA (miR) expression, has to be clarified.  
Aims: Stemming from these data, in this study the effect of an Azacitidine-Lenalidomide 
combination therapy was studied, in both MDS patients and hematopoietic cell lines. The specific 
aims of this study were to evaluate the effect of Azacitidine and Lenalidomide MDS therapy on: 
cell cycle regulation, hematopoietic differentiation, gene mutation and miR expression. 
Results: Lenalidomide alone, via PI-PLCβ1/PKCα pathway, was able to induce a selective G0/G1 
arrest of the cell cycle in del(5q) cells, slowing down their rate proliferation and favouring 
erythropoiesis activation. This effect was also detected in cells treated with the combination of 
Azacitidine and Lenalidomide, which affected also gene mutations and miR profiling. Although the 
mutation profile at baseline was not entirely capable of predicting the clinical effect of Azacitidine 
and Lenalidomide therapy, the presence of specific point mutations affecting three inositide genes 
(PI3KCD, AKT3 and PLCG2) was correlated to and anticipated a negative clinical outcome. 
Moreover, the miR results, although from preliminary experiments, pointed out that Azacitidine 
and Lenalidomide combination therapy altered the expression of several miRs, above all of those 
involved in the regulation of cell proliferation, differentiation and apoptosis. Moreover, the 
differential miR expression was detectable even from the 4th cycle of therapy in responder 
patients, as compared to non-responders. All in all, our data confirm the involvement of nuclear 
inositides, and particularly PI-PLCβ1, in MDS. To our knowledge, our results show for the first time 
that the molecular mutation profiling of inositide genes or a specific mini-cluster of differentially 
expressed miRs, targeting inositide signaling molecules, can be associated with the clinical 
response, either positive or negative, thus possibly predicting the effect of the therapy.  
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Introduction 
1. Phosphoinositides 
Phosphoinositides (PI) are membrane lipids consisting of esterified glycerol molecules with two 
fatty acid residues of which, generally, one is unsaturated and the other is a phosphoric acid 
residue for inositol binding (Krauß and Haucke, 2007; Livermore et al., 2016; Rusten and Stenmark, 
2006; Shewan et al., 2011) (Figure 1).  
 
 
 
 
 
 
 
 
Figure 1. Structure of phosphoinositides 
Inositol is much more stable than glucose, so that phosphorylation processes are allowed on any 
of its 6 carbon atoms to create several compounds (Figure 1) that, nevertheless, show common 
properties. Moreover, thanks to the spatial conformation assumed by the oxygen molecules of the 
phosphoric acid groups, inositides can interact with various proteins through their PH, PX, FYVE, 
ENTH and CALM/ANTH 1,2,3,4 binding domains (Figure 2). These domains show differences in 
specificity and affinity towards phosphoinositides. Some of them, due to their structural 
conformation, only bind one type of phosphoinositide, whereas others are able to recognize 
several different phosphoinositides (Balla, 2005). 
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Figure 2. Structure of the phosphoinositide binding domains with their ligands (Krauß and Haucke, 2007) 
Phosphoinositides are implicated in almost all cellular physiological processes, acting as second 
messengers in spatio-temporal regulation of cell signaling, cytoskeletal remodeling, cell adhesion, 
motility, apoptosis, differentiation and cell cycle. A specific type of phosphoinositide can be found 
in a specific organelle such as, for example, PI(4)P in the Golgi or PI(3)P in the endosomes (Balla, 
2013; Di Paolo and De Camilli, 2006; Shewan et al., 2011; Wymann and Schneiter, 2008). In 
addition to the classical cytoplasmic localization, phosphoinositides are also found in the nucleus, 
where they are regulated independently (Ratti et al., 2017a). These nuclear phosphoinositides 
perform the function of cofactors in different nuclear processes, including DNA repair and 
regulation of transcription, with a pathological relevance. In fact, an imbalance of these signaling 
pathways, caused by a change in the composition of nuclear phosphoinositides, can lead to 
chronic inflammatory diseases, cancer and degenerative syndromes (Cocco et al., 2015b; Follo et 
al., 2013; Ratti et al., 2019). 
 
2. Role of nuclear inositides in cell cycle 
NUCLEAR PI-PLCS  
PI-PLCs are a family of 13 isozymes divided into six families: PI-PLC-β (1–4), - γ (1–2), δ (1, 3, and 
4), - ε, - ζ, and η (1–2) (Gresset et al., 2012). All these PI-PLCs show conserved structural features 
that allow them to hydrolyze PI(4,5)P2, following several ligand bonds with cell surface receptors. 
PI(4,5)P2 hydrolysis results in diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3) synthesis. 
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In turn, IP3 releases Ca2+ that, along with DAG, determines protein kinase C (PKC) activation and is 
involved many cellular mechanisms. Indeed, PKCs can regulate cell cycle progression at all levels, 
interacting with many cell cycle regulatory molecules.  
Among the PI-PLCs that localize within the nucleus PI- PLCs , playing pivotal roles in cell regulation, 
PI-PLCζ is a sperm-specific enzyme that is associated with nuclear infertility mechanisms in relation 
to oocyte activation through Ca2+ release via IP3 pathway (Amdani et al., 2016).  
However, the first discovered nuclear PI-PLC is PI-PLCβ1, whose gene is located on the short arm 
of chromosome 20 (20p12) and results in two splicing variants: PI-PLCβ1a (150 kDa) and PI-PLCβ1b 
(140 kDa), differing one another for the C-terminal sequence (Bahk et al., 1998). Both isoforms 
have a Nuclear Localization Sequence (NLS), but PI-PLCβ1a also has a Nuclear Export Sequence 
(NES). Therefore, PI-PLCβ1a localizes both in the nucleus and cytoplasm, while PI-PLCβ1b is 
primarily located inside the nucleus (Martelli et al., 2005)(Follo et al., 2006). Nuclear PI-PLCβ1 is 
involved in cell cycle control at both G1/S transition and G2/M progression, through the activation 
of PI-PLCβ1/Cyclin D3 or PI-PLCβ1/PKCα/Cyclin B1/Cdk1 pathways (Figure 3).  
 
 
 
 
 
 
 
 
 
Figure 3. Nuclear inositide signaling and cell cycle: nuclear PI-PLCβ1 modulates Cyclin D3 activity affecting G1/S transition and Cyclin 
B1 activity affecting G2/M progression. DAG increase, related to PI-PLCβ1 activity, is responsible for PKCα nuclear translocation. The 
phosphorylation of Lamin B1, by PKCα/Cyclin B1/Cdk1 complex is essential for the mitosis. There are other molecules involved in 
these processes such as DGKs. In particular, DGKα can affect cell cycle progression interacting with DAG and other molecules 
involved in cell cycle regulation such as pRb (Ratti et al., 2018) 
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PI(4,5)P2 SIGNALING 
PI(4,5)P2 seems to be crucial in cell cycle progression, as its synthesis can be observed in the G1/S 
transition of the cell cycle in MEL cells (Clarke et al., 2001). PI(4,5)P2 is mainly produced by PIP5K, 
that can interact with pRb (van den Bout and Divecha, 2009), which is essential in the cell cycle 
control of the progression to S phase. Therefore, the interaction between PIP5K and pRb can lead 
to PIP5K activation and PI(4,5)P2 synthesis, playing a significant role in cell cycle progression. 
Furthermore, PI(4,5)P2 localizes in the interchromatin granular structures, where it could have 
structural and regulatory roles in RNA splicing, interacting dynamically with several chromatin 
structures during the cell cycle progression (Osborne et al., 2001). 
Another kinase implicated in PI(4,5)P2 regulation is PIP4K: it can change the levels not only of 
PI(4,5)P2, but also of PI5P, thus affecting the regulation of several pathways that are involved in 
cell proliferation. PIP4K2A seems, in particular, to be implicated in Acute Myeloid Leukemia (AML). 
When PIP42KA is silenced in THP-1 and MLL-AF9 leukemic cell lines, there is an accumulation of 
p21, a cell cycle inhibitor, that induces a cell cycle arrest and a reduction in cell proliferation, that 
it is not observed if PIP42KA is silenced in normal hematopoietic progenitor cells (Jude et al., 2015; 
Beuvink et al., 2005; Nakano et al., 2013).  
 
DGKs  
Also Diacylglycerol Kinases (DGKs) can be localized inside the nucleus (Evangelisti et al., 2007; Poli 
et al., 2017a), suggesting a role in cell cycle regulation (Payrastre et al., 1992; Raben DM and Tu-
Sekine B., 2008; Ratti et al., 2018; Shulga et al., 2011). DGKs, a family of 10 proteins divided into 5 
classes according to their specific domain composition, can all use ATP to phosphorylate DAG and 
produce phosphatidic acid (PA) (Baldanzi, 2014). This can modulate cell cycle progression and cell 
proliferation (Almena et al., 2013; Goto et al., 2014; Ratti et al., 2017b).  
DGKζ seems to be a negative regulator of cell cycle progression: its overexpression is associated 
with S phase arrest and its inhibition or silencing induces cell cycle progression. DGKζ can also 
control the G1/S transition, through interaction with pRb (Ratti et al., 2018).  
DGKα, under specific stimuli, can shuttle inside and outside the nucleus (Matsubara et al., 2012; 
Wada et al., 1996). Nuclear DGKα shows a positive cell cycle regulation effect, in NPM-ALK 
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oncogene Lymphoma cells, in interleukin-2 (IL-2)-stimulated lymphocytes and in murine models, 
where the pharmacological inhibition of DGKα prevents the excessive CD8+ T-cell expansion and 
IFNγ production (Ruffo et al., 2016; Bacchiocchi et al., 2005; Flores et al., 1999, 1996). Also in K562 
cells DGKα localizes within the nucleus during cell cycle progression. In fact, K562 cells treated 
with DGKα inhibitors showed an important block at the G0/G1 checkpoint and a parallel reduction 
of the S and G2/M phases. This impaired cell cycle phenotype was due to a strong decrease of the 
levels of phosphorylation of pRB, which is an essential process for the detachment of pRb from 
E2F and, in turn, for cell cycle entry into S phase (Poli et al., 2017a).  
 
3. Role of nuclear inositides in cell differentiation 
Nuclear PI-PLCβ1 plays a crucial role in cell differentiation in several distinct cell systems (Figure 4).  
Osteogenic differentiation is induced by the activation of a BMP-2/PI-PLCβ1/alkaline phosphatase 
(ALP) pathway (Ramazzotti et al., 2016). Interestingly, even without BMP-2, the over-expression of 
PI-PLCβ1 still determines a certain level of osteoblast differentiation, albeit reduced. This could 
confirm the capability of PI-PLCβ1 to induce osteogenic differentiation per se, through possible 
downstream molecules. For instance, PI-PLCβ1 is related to miR-124, that can inhibit the 
osteogenic differentiation by regulating Osx/Sp7 (Feng et al., 2011). 
PI-PLCβ1 is also associated with myogenic differentiation (Ramazzotti et al., 2016). During the 
myotube formation, nuclear PI-PLCβ1 increases in C2C12 cells induced to differentiate. 
Interestingly, this PI-PLCβ1 increase is associated with a Cyclin D3 increase, possibly due to the fact 
that Cyclin D3 promoter has a region that could be activated by PI-PLCβ1, possibily through c-jun 
involvement (Faenza et al., 2012). Indeed, this PI-PLCβ1/Cyclin D3 pathway could start with PI-
PLCβ1 catalytic activity, that leads to IP3 synthesis, which is phosphorylated by the Inositol 
Polyphosphate Multikinase (IPMK), with the production of higher phosphorylated inositol species 
such as IP4, IP5, and IP6. In turn, IP5 can induce β-catenin nuclear translocation, activating c-jun, 
and finally Cyclin D3 promoter.  
Nuclear PI-PLCβ1 is involved also in adipocyte differentiation, as during the differentiation of 3T3-
L1 adipocytes there is an up-regulation of PI-PLCβ1. Interestingly, there is a first early phase of 
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differentiation, regulated by PKCα, whereas during the second phase, after a longer induction of 
adipocyte differentiation, there is the nuclear translocation of PI-PLCβ1 (O’Carroll et al., 2009). 
PI-PLCβ1 is involved also in the hematopoietic system, playing pivotal roles in both erythroid and 
myeloid differentiation (Figure 4). Interestingly, this nuclear enzyme has an opposite behavior in 
these two subsystems: during erythroid differentiation PI-PLCβ1 seems to decrease, whereas 
during myeloid differentiation PI-PLCβ1 appears to increase (Cocco et al., 2015a).  
More specifically, in murine erythroleukemia cells (MEL) and in normal CD34+ cells subjected to 
erythropoietin stimulation, PI-PLCβ1 expression decreases. Furthermore, PI-PLCβ1 shows the 
same trend also in Myelodysplastic Syndromes (MDS) cells responding to erythropoiesis 
stimulating agents (Follo et al., 2012).These data suggest that PI-PLCβ1 plays an inhibiting role in 
erythroid differentiation that is countered by PI-PLCγ1, another PI-PLC isozyme that is associated 
with erythroid differentiation.  
 
 
 
 
 
Figure 4. PI-PLCβ1 level changes during cell differentiation: PI-PLCβ1 increases during the normal osteogenic and myogenic 
differentiation in C2C12 cells. PI-PLCβ1 also increases in adipogenic differentiation in 3T3-L1 cells. During erythroid differentiation 
there is a decrease in PI-PLCβ1 level demonstrated in MEL, CD34+, and MDS cells. PI-PLCβ1 seems to increase in MDS cells and also 
in MDS patients samples during the myeloid differentiation induced by Azacitidine (Ratti et al., 2017b) 
 
4. Myelodysplastic Syndromes 
Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of chronic myeloid hemopathies 
with associated symptomatic cytopenias and substantial potential for evolution to acute myeloid 
leukemia (AML) (Prebet and Zeidan, 2016). The WHO (World Health Organization), FAB (French-
American-British) and IPSS/WPSS (International/WHO Prognostic Scoring System) classifications, 
mainly based on the blast number and karyotype, are generally used to divide the patients in two 
major groups: higher and lower risk of AML progression (Nosslinger, 2001).  
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INNOVATIVE THERAPY 
Clinical characterization is essential to divide patients in prognostic risk groups of AML evolution, 
as they need distinct treatment strategies. Indeed, lower risk MDS are usually treated with 
erythropoiesis stimulating agents, while higher risk MDS are addressed to allogeneic 
hematopoietic stem cell transplantation (allo-HSCT) as first choice treatment or, for those who are 
not candidates, hypomethylating agents (HMAs), such Azacitidine, are now the first line therapy. 
Azacitidine is both a hypomethylating and a direct cytotoxic agent for abnormal hematopoietic 
cells. It has been tested also before and after allo-HSCT, but, in this case, their role is still 
undefined (Finelli et al., 2016).  
Much of the difficulty in treating MDS patients relates to their biological heterogeneity, with 
patients having a cohort of disparate cytogenetic and myeloid cell mutational/microRNA (miR) 
profiles (Aleshin and Greenberg, 2018). 
A recent therapy algorithm of MDS is described in Figure 5 (Steensma, 2018).  
 
 
 
 
 
 
 
 
 
Figure 5. Algorithm of MDS therapies (Steensma, 2018) 
 
EPIGENETIC THERAPY 
The main idea of this approach is to pharmacologically reduce the DNA methylation of silenced 
genes in the disease, as well as inhibit the expression of certain protein complexes or single 
proteins, such as DNA methyltransferases, through chromatin remodelling. The main goal of 
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epigenetic therapy in MDS patients is to sustain a correct hematopoiesis, delay the AML evolution 
and ensure a better quality of life (Hofmann and Koeffler, 2005). In 1960, two cytosine analogues 
which showed a cytotoxic and demethylating capacity against DNA, were discovered: 5’-
azacitidine (Azacitidine or AZA) and 5-aza-2'-deoxycytidine (Decitabine or DAC).  
Azacitidine is now widely used in MDS, as the life expectancy of patients with high-risk MDS who 
respond positively to Azacitidine is increased up to 24.5 months, compared to the 15.0 months 
that were obtained only with supportive care (Issa, 2010; Tefferi and Vardiman, 2009). 
 
Azacitidine 
Azacitidine is a cytidine analog in which the carbon atom at position 5 in the pyrimidine ring has 
been replaced by a nitrogen atom, which allows its incorporation into nucleic acids (Figure 6). The 
altered structure of the drug is the cause of its demethylating capacity, as it replaces the normal 
cytosines and prevents the DNA methyltransferases binding, resulting in gene re-expression 
(Christman et al., 1983; Leone et al., 2002).  
Azacitidine is phosphorylated by the uridine-cytidine kinase, and the Azacitidine trisphosphate is 
able to integrate into the RNA, producing the disassembly of the polyribosomes and the inhibition 
of protein synthesis. Furthermore, following its transformation to 5-aza-2'-deoxycitidine, 
Azacitidine can also be incorporated into DNA, to a lesser extent than RNA, where it leads to a 
blockage of methylation, due to its ability to covalently bind the DNA methyltransferase and cause 
its degradation.  
The efficacy of azacitidine as an antitumor drug is the result of two different mechanisms of 
action, depending on the dosage: at higher concentrations, both in vivo and in vitro, it shows an 
antileukemic and cytotoxic capacity, inhibiting DNA synthesis, while in minor doses it has a 
differentiation activity, stimulating the DNA hypomethylation (Leone et al., 2002).  
Azacitidine has been tested on various types of tumors, showing much more efficacy in 
hematologic malignancies than in solid ones. Compared to conventional chemotherapeutic drugs, 
the effect promoted by Azacitidine can be appreciated only after a certain number of cycles and 
with continuous therapy over time, showing better results than traditional drugs and with fewer 
side effects. This is due to the fact that Azacitidine effects are much more marked in the S-phase 
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and in rapidly dividing cells (Christman et al., 1983; Issa, 2010; Kaminskas et al., 2005; Leone et al., 
2002; Tefferi and Vardiman, 2009; Yamazaki and Issa, 2013).  
 
Figure 6. Molecular structure of azacitidine 
 
IMMUNOMODULATORY THERAPY 
The use of cancer immune therapy for the treatment of hematological malignancies is an obvious 
treatment option, as the tumor cells in the blood, lymphoid tissue, and bone marrow are easily 
accessible to effector immune cells. However, one drawback of cancer immune therapy for 
hematological malignancies is that the effector immune cells may potentially be malignant 
themselves. MDS are characterized by a dysregulation of the immune system, and several 
treatment strategies try to circumvent this deregulation(Holmström and Hasselbalch, 2019). 
 
Lenalidomide 
Lenalidomide (trade name Revlimid®) is an immunomodulatory drug derived from thalidomide, 
which was used in the 1950s as an anti-emetic drug during pregnancies (Figure 7). 
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Figure 7. Thalidomide structure 
 
The production of thalidomide analogues (Lenalidomide and Pomalidomide) was born in response 
to the need to decrease the risk that thalidomide had to induce fetal malformations, while 
preserving its immunomodulatory pharmacological properties. In hematology, these compounds 
were used firstly for the therapy of multiple myeloma (MM) but, after noting their high efficacy as 
agents with immunomodulatory, anti-angiogenic, anti-inflammatory, anti-proliferative and pro-
apoptotic action, they were also tested in MDS (Matsuoka et al., 2010).  
In MDS, Lenalidomide has a specific pro-apoptotic and anti-proliferative effect, above all in cell 
clones bearing a deletion of the long arm of the chromosome 5 [del(5q)]. At the same time, it is 
able to suppress the production of pro-inflammatory cytokines and increase the activation of T 
and NK cells, inducing an immune response (Hosono et al., 2017). That is why Lenalidomide is 
currently the first choice therapy for patients diagnosed with MDS and showing a del(5q) 
karyotype (Stahl and Zeidan, 2017), as in these patients Lenalidomide may suppress the del(5q) 
clone, sustain the immune response in lieu of the inflammatory one, and restore a normal 
erythropoiesis (Basiorka et al., 2016; Narla et al., 2011).  
 
5. Role of miRs and gene mutations in MDS 
miRs 
miRs are non-coding RNAs of 20-23 nucleotides encoded by specific genes present in the cellular 
genome. They are fundamental for the regulation of gene expression of about 60% of human DNA, 
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being involved in the processes of translation and degradation of different mRNAs. miRs are 
produced at the nuclear level following the action of RNA polymerase II and in some cases of RNA 
polymerase III. In the nucleus, they are processed by specific endonucleases (Drosha) and 
reassembled in hairpin structures forming the pri-miRs (Figure 8). The pri-miRs are then exported 
into the cytosol, via the Esportin-5 transport, where they are cut by Dicer endonucleases. 
Following this cut, two strands of single-stranded RNA are formed, and only one of them is 
preserved. This filament subsequently binds to an Argonauta protein, forming the RISC protein 
complex (RNA induced silencing complex), which is the real effector of the gene regulation. 
The miRs belonging to the RISC complex usually bind the 3'-UTR non-coding regions of the 
different mRNAs and, depending on this binding, they induce the degradation or inhibition of the 
translation: if there is total complementarity between the two molecules there is degradation, 
otherwise the translation is inhibited. 
 
 
 
 
 
Figure 8. Mechanism of biogenesis and action of miRNAs 
Mutations or de-regulation of miRs that regulate epigenetic or developmental processes, 
proliferation, differentiation and cell death are involved in MDS (Milunović et al., 2016). 
Specifically, the analysis of miRs could result in a more accurate comprehension of the molecular 
framework of the disease, leading to the best choice of the therapeutic treatment (and possibly 
also to the development of new ones), that could be more effective and specific for the patient. 
Among the miRs already seen to be involved in MDS, there are miR-145 and miR-146a 
(chromosome 5), whose deletion or down-regulation causes cytopenia, thrombocytosis, 
megakaryocytic dysplasia and a greater risk of evolution in AML. Other miRs that play a role in 
MDS are miR-194-5p (chromosome 1) and miR-320a (chromosome 8) (Choi et al., 2015). MiR-194-
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5p is a cell growth inhibitor and a promoter of apoptosis, as it regulates p53 (specifically it 
suppresses E3 ubiquitin-protein ligase Mdm2), and its down-regulation has been associated with a 
decrease in life expectancy of MDS patients. MiR-320a is a regulator of SMAR1 (an important pro-
apoptotic factor) and its up-regulation has been associated with an inhibition of erythroid 
differentiation, with a consequent deterioration of peripheral blood cytopenia that is typically 
found in MDS patients (Choi et al., 2015; Kuang et al., 2016). 
 
GENE MUTATIONS 
MDS frequently show mutations in genes involved in RNA splicing (e.g. SF3B1, SRSF2, U2AF1, 
ZRSR2; approximately 40-60% of patients) (Armstrong et al., 2018; Pellagatti and Boultwood, 
2017), DNA methylation (i.e. DNMT3A, TET2, IDH1, IDH2; approximately 30–40%) or chromatin 
remodelling (i.e. ASXL1, EZH2; approximately 15–25%), that are retrieved at diagnosis or can be 
specifically acquired during follow-up (Kennedy and Ebert, 2017; Stosch et al., 2018). For instance, 
not only ASXL1 mutations are associated with impaired hematopoiesis and are predictive of a poor 
(Mangaonkar et al., 2018; Uni et al., 2019), but also TP53, EZH2, SF3B1 and SRSF2 mutations have 
been recognized as being unfavorable for survival (Arbab Jafari et al., 2018; Gangat et al., 2018; 
Pellagatti et al., 2018). Moreover, specific gene mutations, such as those affecting TET2, have been 
associated with a favourable response to Azacitidine (Unnikrishnan et al., 2017), while the 
acquisition of TP53 or NRAS mutations has recently been related to resistance to Lenalidomide (da 
Silva-Coelho et al., 2017; Jädersten et al., 2011). 
 
6. Nuclear inositides and MDS Therapy 
Patients with MDS need a lot of time to be able to benefit of the effect of Azacitidine and, 
sometimes, they can lose their positive response to the treatment after a certain time (Follo et al., 
2008; Nazha et al., 2016). For these reasons, molecular markers able to predict the clinical 
outcome and responsiveness to HMAs are needed, in order to reach a better, safer and more 
specific use of Azacitidine or other HMAs (Finelli et al., 2016). 
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Nuclear PI-PLCβ1 in MDS is epigenetically relevant. Several studies have shown that PI-PLCβ1 is a 
specific molecular target for Azacitidine (Cocco et al., 2015a; Follo et al., 2009, 2008). Actually, 
high risk MDS patients that respond to the drug have shown an early increase of nuclear PI-PLCβ1 
expression, a decreased expression of phosphorylated Akt, an induction of normal myeloid 
differentiation (through MZF-1 recruitment), and a better prognosis (Cocco et al., 2015a; Follo et 
al., 2009; Follo et al., 2015; Piazzi et al., 2015). 
At a clinical level, it is important to note that PI-PLCβ1 increase is not only related to a favorable 
outcome, but also to a longer duration of response. In fact, MDS patients treated with Azacitidine 
and showing a favourable long response displayed an early increase of nuclear PI-PLCβ1, 
detectable from the very first cycles of Azacitidine treatment (Cocco et al., 2015a). Moreover, PI-
PLCβ1 can be considered as a dynamic marker of response, as its reduction can be associated with 
a loss of response even in patients that had, at first, a positive response to Azacitidine (Filì et al., 
2013). These data could therefore be used to early divide MDS patients into two groups: the ones 
who will probably show a favorable long-term response to Azacitidine and the ones who would be 
refractory to the treatment and thus could avoid its intrinsic risks (Cocco et al., 2015b).  
As for Lenalidomide, recent studies showed that in Lenalidomide-sensitive del(5q) cell lines, Akt 
phosphorylation is inhibited and a cell cycle arrest is detected (Gandhi et al., 2006). Interestingly, 
Akt signalling is involved also in erythropoiesis (Follo et al., 2012; Mongiorgi et al., 2016a). In fact, 
during both erythropoiesis and erythropoietin-induced erythroid differentiation of CD34+ 
progenitor cells, phosphoinositides phosphorylated by Phosphatidylinositol-4,5-bisphosphate 3-
kinase (PI3K) can act as second messengers to directly activate Akt and certain isoforms of PKC, 
particularly PKCα (Myklebust et al., 2002; Poli et al., 2014b).  
 
 17 
Aims 
The aims of this study were to evaluate the effect of Azacitidine and Lenalidomide MDS therapy on 
• cell cycle regulation 
• hematopoietic differentiation 
• gene mutation 
• miR expression 
MDS are characterized by altered gene mutations, epigenetic processes and a peripheral 
cytopenia. The use of hypomethylating drugs, including Azacitidine, is an attempt to restore the 
correct epigenetic architecture, which could restore the normal proliferation and differentiation. 
On the other hand, Lenalidomide is an immunomodulatory drug that is currently used in del(5q) 
MDS cells, where it can sustain erythropoiesis. Generally, high-risk MDS patients show a positive 
response to Azacitidine, and del(5q) MDS patients favourably respond to Lenalidomide. 
Nevertheless, some patients can become refractory to either drug during the therapy, and for 
them, but more generally for all MDS, it would be important to find out new molecular dynamic 
markers of response, either positive or negative. 
Phosphoinositide (PI) signalling pathways, and particularly those regulated by nuclear PI-PLCβ1, 
play an essential role in cell proliferation and differentiation, mainly in hematopoietic cells. 
Indeed, their impairment results in a deficient regulation of hematopoiesis, possibly leading to 
hematological malignancies. Furthermore, some PIs showed an epigenetic deregulation, like a 
promoter hypermethylation, that could be relevant in clinical hematology. 
Starting from these data, in this study the effect of an Azacitidine-Lenalidomide combination 
therapy was studied, in both MDS patients and hematopoietic cell lines. At first, hematopoietic cell 
lines were used to determine the effect of Azacitidine and Lenalidomide treatment, alone or in 
combination, on cell cycle, erythropoiesis molecules (both surface markers and globin genes) and 
inositides, focusing on PI-PLCβ1-dependent pathways.  
On the other hand, MDS cells were tested for gene mutations and miR expression, as both 
Azacitidine and Lenalidomide could be associated with the acquisition of specific gene mutations 
or miR expression that could be important not only in terms of diagnosis and prognosis, but also to 
identify new molecular markers for the development of innovative targeted therapies. 
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Materials and Methods 
1. Cell Lines and Treatments 
Human HL60 promyelocytic cells, acute myeloid leukemia MOLM-13 (AML secondary to MDS), 
OCI-AML3 and THP-1 cells, Namalwa CSN.70 Burkitt lymphoma cells (i.e. del(5q) cells) and U937 
histiocytic lymphoma cells (i.e. non-del(5q) cells) were cultivated at 37°C with 5% CO2 in RPMI 
1640 medium (Cambrex Bio Science, Verviers, Belgium) supplemented with 10% heat-inactivated 
fetal bovine serum and streptomycin/penicillin at an optimal cell density of 0.3-0.8 x 106 cells/mL. 
Cells were treated with 5µM Azacitidine and 1µM Lenalidomide (CDS022536, Sigma-Aldrich), alone 
or in combination for 1 to 10 days, in order to give cells a concentration comparable to the plasma 
concentration reached in clinical uses. Samples were taken at days 1 (24h), 2 (48h), 6, 8 and 10 to 
monitor the molecular effect of the therapy. 
 
2. Flow cytometric analysis of cell cycle 
Cells were cultivated in RPMI medium (Cambrex Bio Science) with the drugs. The subdiploid DNA 
content was evaluated using an FC500 Dual Laser Flow Cytometer with the appropriate software 
(System II, Beckman Coulter) (Follo et al., 2011). At least 10,000 events/sample were acquired. 
 
3. Flow cytometric detection of Glycophorin A and CD71 levels 
For the detection of Glycophorin A (GPA) and CD71 surface antigens, cells were cultivated in RPMI 
medium (Cambrex Bio Science) with the drugs. The percentage of positive cells was quantified 
using an FC500 Dual Laser Flow Cytometer with the appropriate software (System II, Beckman 
Coulter) (Follo et al., 2011). At least 10,000 events/sample were acquired.  
4. Nucleic Acids Extraction 
Total RNA was isolated from cell lines and total MNCs from MDS patients and healthy subjects by 
using the RNeasy Mini Kit (Qiagen Ltd, Valencia, CA, USA) according to the manufacturer’s 
protocol, then RNA was retro-transcribed. 
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5. Analysis of Gene and Protein Expression 
The gene expression of PI-PLCβ1a, PI-PLCβ1b, Beta-Globin and Gamma-Globin was quantified by 
using a specific TaqMan Real-Time PCR method (Applied Biosystems, Foster City, CA, USA), as 
described elsewhere (Follo et al., 2009). A pool of healthy subjects was used as an internal 
reference, whilst GAPDH was the housekeeping gene. Due to the low amount of MDS cells, protein 
expression was examined only by immunocytochemical analyses on MNCs, as previously 
illustrated (Blalock et al., 2011). For cell lines, we carried out a Western blot analysis, and the 
nuclear/cytoplasmic fractionation was performed as already reported (Poli et al., 2014b). Beta-
tubulin was used as a control of equal protein loading in total lysates, whereas purity of nuclear 
and cytoplasmic fractions was tested using either Beta-tubulin (cytoplasmic marker) or H3A 
(nuclear marker) antibodies. 
 
6. MDS patients: Diagnosis, Therapies and Outcome 
PATIENTS’ CHARACTERISTICS 
Bone marrow (BM) and peripheral blood (PB) samples were obtained from 44 higher risk MDS 
patients (Greenberg et al., 2012; Vardiman et al., 2002) who had given informed consent 
according to the Declaration of Helsinki. All samples came from several Italian hematological 
centers and were centralized at the Institute of Hematology "L. and A. Seràgnoli", Policlinico 
Sant’Orsola–Malpighi Hospital, Bologna, Italy. Patients’ characteristics are reported in Table 1 (for 
patients treated with Lenalidomide alone) and in Table 2 (for patients treated with both 
Azacitidine and Lenalidomide).  
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Characteristics 
General  
No. patients 16 
Male/female ratio 4:12 
Median age, years (range) 77,5 (69-90) 
Cytogenetic Categories (IPSS)  
Good 14 
Intermediate 2 
Cytogenetic Categories in more detail  
-5q 14 
other 2 
Table 1. Patients’ characteristics for patients treated with Lenalidomide alone 
Characteristics 
General  
No. patients 44 
Male/female ratio 27:17 
Median age, years (range) 72 (48-83) 
Cytogenetic Categories (WPSS)  
Good 17 
Intermediate 11 
Poor 14 
Not Determined 2 
Cytogenetic Categories in more detail  
Normal 15 
Del(20q) 2 
Monosomy 7 6 
Trisomy 8 7 
Complex (More than 3 chromosomal aberrations) 8 
Unknown 2 
Other 4 
 
* More than three chromosomal aberrations 
† 100% of Patients showing cytogenetic alterations on Chromosome 20q  
Table 2. Patients’ characteristics for patients treated with both Azacitidine and Lenalidomide 
PATIENTS’ TREATMENT AND EVALUATION OF RESPONSE 
Patients were treated with Lenalidomide (10 mg/day, days 1-21 or 6-21, orally) alone or 
Azacitidine (75 mg/m2/die for 7 days every 28 days) and Lenalidomide (10 mg/day, days 1-21 or 6-
21, orally) every 4 weeks. Patients were considered clinically evaluable, according to the IWG 
response criteria (Cheson et al., 2006), only after at least 6 cycles of treatment. Patients were 
considered evaluable if they reached at least 6 cycles of therapy or showed either a positive or 
negative response within the first 4 cycles (T4). We also recorded the time to AML evolution 
(calculated from the date of diagnosis according to the WHO classification (Arber et al., 2016), i.e. 
>30% marrow blasts), survival and causes of death (Tables 3 and 4). Data were censored when 
patients died or were lost during follow-up.  
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For patients treated with Lenalidomide alone, 16 low-risk del(5q) MDS patients were treated. 
Eleven patients were evaluable for response. According to the revised IWG criteria (Cheson et al., 
2006), ten patients (90%) showed a favorable response to the treatment (5 CR, 3 HI-E and 2 HI-E 
with cytogenetic response). The remaining patient had a stable disease (Table 3). 
For patients treated with both Azacitidine and Lenalidomide (Table 4), it is important to note that 
10 patients discontinued therapy before the 6th cycle (T6). Therefore, only 34 patients were 
evaluated clinically for hematologic response, and had both clinical and molecular analyses 
correlated. Patients who achieved a complete remission (CR), partial remission (PR), or any 
hematologic improvement (HI), according to the revised IWG criteria (Cheson et al., 2006), were 
considered responders, whereas all the other outcomes were defined as non responders. The 
duration of response was assessed in patients who showed a clinical response to treatment. 
Table 3. Clinical, hematologic, and cytogenetic characteristics of the MDS patients treated with Lenalidomide alone 
 Diagnosis 
Screening Age Sex Karyotype No. Cycles Clinical Outcome 
Survival 
(Months) 
Cause of 
Death  WHO R-IPSS 
1 5q- LOW 10/2010 80 F del(5q) 56 HI-E 70  
2† 5q- LOW 04/2011 90 M del(5q) 1 NE 1 Stroke 
3 RA LOW 04/2011 86 M del(5q); del(20)(q11;q13) 1 NE 6  
4† 5q- LOW 09/2012 83 F del(5q) 5 CR 14 Pneumonia 
5† 5q- LOW 02/2012 72 F del(5q) 29 CR 32 Sepsis 
6 5q- LOW 01/2015 80 F del(5q) 16 HI-E +cyt.resp. 20  
7 5q- INT 11/2015 81 F del(5q) 6 SD 10  
8 5q- LOW 02/2015 74 M del(5q) 17 HI-E +cyt.resp. 19  
9 RA INT 01/2011 71 F del(5q); t(2;11) 29 HI-E 68  
10 5q- LOW 04/2014 72 F del(5q) 1 NE 29  
11 RA INT 05/2014 76 F del(5q); del(20q) 2 NE 28  
12† RAEB-1 INT 06/2015 70 M del(5q)(q22q33) 3 NE 7 
Brain 
Tumor 
13 5q- LOW 02/2013 82 F del(5q) 40 CR 43  
14 5q- INT 07/2009 69 F del(5q) 24 CR 86  
15† RA INT 04/2011 79 F del(2p)(p21p25); del(5q)(q22q23) 14 CR 28 Sepsis 
16 RA LOW 07/2016 76 F del(5q)(q13q33) 5 HI-E 5  
Abbreviations. † Deceased Patient. WHO: World Health Organization; 5q-: MDS with isolated del(5q); RA: Refractory Anemia; 
RAEB-1: Refractory Anemia with Excess of Blasts-1; R-IPSS: Revised International Prognostic Scoring System; LOW: Low-Risk; INT: 
Intermediate; F: Female; M: Male; HI-E: Hematologic Improvement - Erythroid; NE: Not Evaluable; CR: Complete Remission; HI-
E+cyt. resp: Hematologic Improvement - Erythroid with Cytogenetic Response; SD: Stable Disease. 
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Table 4. Clinical, hematologic, and cytogenetic characteristics of the MDS patients treated with both Azacitidine and Lenalidomide 
 Age Sex 
Diagnosis 
Screening 
Karyotype  
[No. 
Metaphases 
with 
aberrration]  
Clinical 
Outcome 
Total 
Cycles 
Duration 
of 
Therapy 
(Months) 
Time to 
First 
Response 
(Cycles) 
Duration 
of 
Response 
(Months) 
Survival 
(Months) 
Time to 
AML 
Evolution 
(Months) 
Cause of Death 
WHO WPSS 
1
†
 67 M RAEB-2 VERY-HIGH 25/03/2013 COMPLEX SD 10 10 NA NA 14 8 AML 
2
†
 67 F RAEB-2 HIGH 02/04/2013 46, XX CR 30 28 6 24 35 28 OVARIAN CANCER 
3
†
 71 M RAEB-2 HIGH 29/04/2013 47, XY, +8 [8] mCR 38 36 4 10 41 36 AML, INFECTION 
4
†
 76 F RAEB-2 HIGH 13/05/2013 46, XX [1] HI 8 8 4 5 12 9 AML, CACHEXIA 
5
†
 68 M RAEB-1 HIGH 13/05/2013 COMPLEX SD 9 9 NA NA 14  
PNEUMONIA, 
CARDIAC 
FAILURE 
6
†
 67 M RAEB-2 HIGH 23/05/2013 46, XY PR 10 10 2 6 30 10 AML 
7
†
 72 M RAEB-1  HIGH 26/06/2013 
46, XY, 
del(7)(q22;34) 
[20]; del(7q31) 
[18] 
SD 8 8 NA NA 22 20 CEREBRAL HEMORRHAGE 
8 82 M RAEB-2 HIGH 28/06/2013 46, XY CR 41 42 2 40 42    
9 67 F RAEB-1 HIGH 01/07/2013 47, XX,+8 HI+mCR 12 18 2 (mCR); 5 (HI) 
8 (HI);  
16 (mCR) 42    
10 73 F RAEB-1 INT 10/07/2013 45, X, del(X), del(20q) HI+mCR 38 42 
3 (HI)  + 
4 (mCR) 
35 (HI); 
34 (mCR) 42    
11
†
 75 F RAEB-1 HIGH 10/07/2013 47, XX,+8 HI 20 21 1 19 28 21 DISEASE PROGRESSION 
12 76 M RAEB-1 INT 22/07/2013 46, XY HI+mCR 8 8 1 5 (HI);  6 (mCR) 38    
13
†
 74 M RAEB-2 ND 24/07/2013 ND NA 1 1 NA NA 2  PNEUMONIA 
14
†
 78 M RAEB-2 HIGH 05/08/2013 46, XY HI 19 25 8 9 27 25 AML 
15
†
 72 M RAEB-2 HIGH 28/08/2013 46, XY, del(5), del(9) NA 2 3 NA NA 12  
WORSENING 
OF CLINICAL 
CONDITIONS 
16 70 M RAEB-2 HIGH 29/08/2013 46, XY CR 27 40 2 38 40    
17
†
 75 F RAEB-2 HIGH 03/09/2013 46, XX, t(2;15)(q23;q26) DP 2 2 NA NA 5 2 AML 
18
†
 72 F RCMD-RS HIGH 09/09/2013 COMPLEX HI+mCR 13 14 2 11 16 15 AML, SEPSIS 
19
†
 62 M RAEB-1 HIGH 17/09/2013 46, XY, del(7), +X, [18] CR 6 7 1 5 14  
CARDIAC 
EVENT 
20
†
 70 F RAEB-2 HIGH 23/09/2013 46, XX NA 2 2 NA NA 2  COPD 
21
†
 82 M RCMD HIGH 23/09/2013 47, XY,+8,-9,+3mar HI 20 28 6 18 28  
RESPIRATORY 
FAILURE 
22 82 M RAEB-2 HIGH 25/09/2013 46, XY, del(20q) CR   36 39 1 38 39    
23
†
 68 M RCMD HIGH 03/10/2013 45, XY, del(7) HI 3 3 1 2 3  SUDDEN DEATH 
24 75 M RAEB-2 VERY-HIGH 28/10/2013 
45, XY, del(7), 
del(20)(q11)[3] / 
46, XY [17] 
NA 1 1 NA NA 35    
25
†
 66 F RAEB-2 HIGH 15/10/2013 46, XX SD 8 8 NA NA 14 14 AML 
26
†
 77 M RAEB-2 HIGH 30/10/2013 46, XXYY [5] NA 1 1 NA NA 5  HEART FAILURE 
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27
†
 48 F RAEB-2 VERY-HIGH 06/11/2013 47, XY, +8 CR 16 15 2 11 26  
DISEASE 
PROGRESSION 
28
†
 64 F RAEB-1 INT 06/11/2013 46, XX HI 10 10 5 3 12  PULMONARY CARCINOMA 
29
†
 79 F RAEB-2 ND 13/11/2013 ND NA 2 2 NA NA 3  HEART ATTACK 
30
†
 66 M RAEB-2 VERY-HIGH 15/11/2013 47, XY, +8 HI 9 9 3 5 10  
WORSENING 
OF CLINICAL 
CONDITIONS 
31
†
 75 F RAEB-2 HIGH 22/11/2013 46, XX  HI 10 10 2 7 11 11 AML 
32
†
 83 M RAEB-2 HIGH 04/02/2014 47, XX, +8 [5] SD 6 6 NA NA 11 9 AML 
33
†
 71 F RAEB-2 VERY-HIGH 17/02/2014 COMPLEX CR 7 7 2 5 12 9 AML, SEPSIS 
34
†
 66 F RAEB-2 VERY-HIGH 10/03/2014 COMPLEX DP 1 1 NA NA 2 1 
AML, 
INFECTION 
35 72 M RAEB-1 VERY-HIGH 14/04/2014 COMPLEX HI+mCR 11 11 
4 (HI 
+mCR) 6 (HI) 32    
36
†
 69 M RAEB-2 HIGH 19/05/2014 46, XY mCR 6 6 2 3 16 13 AML 
37 70 M RAEB-1 HIGH 19/05/2014 46, XY, del(7q31) SD 7 9 NA  NA 31    
38
†
 77 F RAEB-2 VERY-HIGH 19/05/2014 COMPLEX NA 2 4 NA NA 4  
BILATERAL 
PNEUMONIA 
39
†
 82 F RAEB-1 VERY-HIGH 04/08/2014 COMPLEX NA 1 2 NA NA 7 3 AML 
40
†
 80 M RAEB-2 VERY-HIGH 15/09/2014 
46, XY, t(9,17) 
(p36;q23) [19] NA 2 2 NA NA 2  
CACHEXIA, 
HEPATIC 
FAILURE 
41
†
 78 M RAEB-2 HIGH 19/08/2014 46, XY HI+mCR 17 16 2 (HI);  2 (mCR) 
14 (HI); 
14 (mCR)  17  UNKNOWN 
42 74 M RAEB-2 VERY-HIGH 18/08/2014 
46, XY, del(7) 
[1] CR 26 28 1 27 28    
43
†
 66 M RAEB-2 HIGH 20/10/2014 46, XY NA 2 2 NA NA 7  RESPIRATORY FAILURE 
44 76 M RAEB-2 HIGH 09/12/2014 46, XY mCR  22 25 4 21 25    
7. Isolation of MNCs from peripheral blood samples 
For in vitro experiments, peripheral blood MNCs were isolated by Ficoll-Paque (GE Healthcare, 
Waukesha, WI, USA) density-gradient centrifugation, according to the manufacturer’s instructions. 
All analyses were performed on samples from patients at baseline, and subsequently, once a 
month during therapy. MNCs from healthy subjects were also extracted. 
 
8. Illumina and Ion Torrent Next Generation Sequencing 
The mutational profile of the MDS patients was determined using a TruSeq Custom Amplicon next-
generation sequencing gene panel (32 recurrently mutated genes in myeloid malignancies) and 
TruSeq Amplicon 2.0 BaseSpace app workflow (Pellagatti et al., 2016). Briefly, amplicon libraries 
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were generated from 250ng of genomic DNA prior to 2x150bp paired-end sequencing on a Miseq 
platform. Variants were determined using Somatic Variant Caller (Illumina) prior to annotation and 
filtering using Illumina VariantStudio v.2.2 with criteria previously described (Pellagatti et al., 
2016). 
Moreover, 31 inositide-specific point mutations and small indels were also examined using the Ion 
Torrent S5 with an Ion AmpliSeq™ On-demand Panel designed to analyze 31 inositide-specific 
genes (Thermo Fisher Scientific). Successful sequencing required a minimum of 10ng DNA. Library 
construction was performed using the Ion AmpliSeq™ Library Kit (Thermo Fisher Scientific). The 
library was quantified using the Ion Libray TaqMan TM Quantitation Kit (Thermo Fisher Scientific) 
after ligation with the Ion Xpress TM Barcode Adapters (Thermo Fisher Scientific), following 
manufacturer's instructions. Sequence alignment and analysis were performed using the Ion 
Torrent Suite Software and the Ion Reporter software (Thermo Fisher Scientific). Sequencing 
alignment was viewed by the Integrative Genomics Viewer Software (Broad Institute, Cambridge, 
MA, USA) using Human Genome Build 19 (Hg19) as the reference (Thorvaldsdottir et al., 2013). A 
minimum coverage depth per amplicon of 250 was required; variant frequency of 10% and higher 
was considered positive. Somatic non-synonymous mutations were reported. Raw sequence data 
were available to reanalyze sequencing reads for possible amplifications, comparisons between 
paired samples, and confirmation of negative results in regions of interest.  
 
9. miR analysis  
BIOTINYLATION AND MICROARRAY HYBRIDIZATION 
The miR protocol involved the hybridization on a chip of 500-1000ng of total RNA. At first, an 
equal amount of RNA was biotinylated at T0, T4 and T8 for each patient, using the FlashTagTM 
Biotin HSR RNA Labeling Kit (ThermoFischer) according to the manufacturer’s instructions. The 
subsequent hybridization was performed using the Affymetrix Gene Chip miRNA Array 
(ThermoFisher), according to the manufacturer’s protocol. 
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BIOINFORMATICS DATA PROCESSING 
The data obtained by the microarray scanning were bioinformatically analyzed. A specially created 
matrix was subjected to the RMA normalization function, which allows a standardization of the 
fluorescence signal emitted by the various microarrays, and subsequently to the lm-Fit (linma) 
function, which allows to validate the data obtained by performing a Specific T-test optimized for 
this process. Other significant values that have been analyzed are the P-Value, the average 
expression, and the Log for Change, all expressed on a logarithmic scale. Each miR probe 
corresponds to a specific code (ID) reported on the miRNA Array library file package (Affymetrix), 
which allows its identification, in order to know its genomic coordinate and possibly its function. 
 
10. Statistical Analyses 
All statistical analyses were performed using the GraphPad Prism 5.0 Software (GraphPad 
Software, La Jolla, CA, USA). All values with p<0.05 were considered statistically significant. Gene 
mutations were analyzed by gene frequency, loci altered, pathways involved and correlated to 
clinical parameters, including OS, leukemia-free survival (LFS) and response to treatment. Survival 
analyses were done according to the Kaplan-Meier method and compared using the Log-rank test.  
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Results 
1. Nuclear inositides and Azacitidine 
As previously reported, Azacitidine alone was able to specifically target PI-PLCβ1, in both cell lines 
and in MDS cells (Figure 9). This lead to the recruitment of MZF-1 transcription factor on PI-PLCβ1 
promoter sequence and the subsequent induction of a normal hematopoietic differentiation. 
 
 
 
 
 
 
 
 
 
Figure 9. Azacitidine treatment induces PI-PLCβ1 demethylation, thus recruiting MZF-1 transcription factor, to restore differentiation 
 
2. Nuclear inositides and Lenalidomide in del(5q) Cells 
CELL CYCLE 
Lenalidomide induced a significant accumulation in the G0/G1 phase of Namalwa CSN.70 cells (i.e. 
del(5q) cells) after 6 and 8 days of treatment (+16,6% and +19,3%, respectively), before being 
reduced at day 10 of the treatment. On the contrary, U937 cells (i.e. non-del(5q) cells) showed a 
slight increase of G0/G1 phase of cell cycle only after 8 days of treatment (+4,1%), before being 
reduced at day 10 of the treatment (Figure 10).  
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Figure 10. Cell cycle in Namalwa CSN.70 and U937 cells during Lenalidomide treatment 
 
CYCLIN EXPRESSION 
Namalwa CSN.70 cells (i.e. del(5q) cells) displayed a significant increase of p21 and p27, a slight 
decrease of Cyclin D3 and an almost constant low amount of Cyclin E. On the contrary, the 
expression of p21, p27 and Cyclin D3 was maintained in U937 cells (i.e. non-del(5q) cells), whereas 
Cyclin E was induced in the last days of treatment with Lenalidomide (Figure 11). 
 
 
 
 
 
 
 
Figure 11. Cell cycle proteins in Namalwa CSN.70 and U937 cells during Lenalidomide treatment 
 
ERYTROPOIESIS 
Namalwa CSN.70 cells (i.e. del(5q) cells) displayed a significant increase of GPA (+29,72%), but not 
of CD71 (-10,06%) after 8 days of treatment. Conversely, the treatment with Lenalidomide induced 
a significant increase of both GPA and CD71 in U937 cells (i.e. non-del(5q) cells) after 8 days of 
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treatment (+12,88% and +17,34%, respectively), which was maintained at day 10 of treatment. 
(Figure 12). 
 
 
 
 
 
 
 
 
 
Figure 12. Flow-cytometric analysis of erythropoiesis in Namalwa CSN.70 and U937 cells during Lenalidomide treatment 
 
As for erythropoiesis molecular markers, Namalwa CSN.70 cells (i.e. del(5q) cells) treated with 
Lenalidomide showed a significant decrease of Gamma/Beta-Globin ratio (Student’s t-test, p<0.05 
vs. baseline, 95% CI -0,04 to -1,63). In contrast, PI-PLCβ1a showed an increase only in the last days 
of treatment of Namalwa CSN.70 cells (Student’s t-test, p>0.05 vs. baseline, 95% CI -0,87 to +0,74), 
whereas the amount of PI-PLCβ1b mRNA was almost constant (Student’s t-test, p>0.05 vs. 
baseline, 95% CI 9 -0,02 to +0,02). As for U937 cells (i.e. non-del(5q) cells), they displayed an 
increase of Gamma/Beta Globin ratio, although without a statistically significant difference 
between pre- and post-treatment (Student’s t-test, p>0.05 vs. baseline, 95% CI +0,01 to +0,07). 
U937 cells also showed a late increase of PI-PLCβ1a (Student’s t-test, p>0.05 vs. baseline, 95% CI 
+0,01 to +0,05, while PI-PLCβ1b was almost constant (Student’s t-test, p>0.05 vs. baseline, 95% CI 
-0,01 to +0,02). 
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Figure 13. Gene expression analysis of erythropoiesis markers in Namalwa CSN.70 and U937 cells during Lenalidomide treatment 
 
INOSITIDE SIGNALLING 
Namalwa CSN.70 cells (i.e. del(5q) cells) showed a very slight increase of PI-PLCβ1 in the last days 
of treatment with Lenalidomide, whilst PKCα was significantly reduced. On the contrary, U937 
cells (i.e. non-del(5q) cells) displayed an almost constant amount of PI-PLCβ1 and PKCα during 
Lenalidomide treatment (Figure 14). 
 
 
 
 
 
Figure 14. Panel of total protein expression of inositide signalling in Namalwa CS.70 and U937 cells 
 
After 8 days of treatment, PKCα appeared to be highly localized inside the nucleus of Namalwa 
CSN.70 cells (i.e. del(5q)cells) and it was barely expressed in the cytoplasmic fraction of this cell 
line, where PI-PLCβ1 was detectable, especially at day 10 of treatment. On the contrary, U937 cells 
did not show a nuclear translocation of PKCα or a cytoplasmic localization of PI-PLCβ1 after 
Lenalidomide treatment (Figure 15). 
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Figure 15. Panel of protein expression of inositide signalling in Namalwa CS.70 and U937 nuclear/cytoplasmic fractions 
 
3 Lenalidomide effect on MDS Patients 
The ratio between Gamma and Beta-Globin mRNAs was quantified in MDS cells at baseline and 
during the therapy (Figure 16). A reduction of Gamma/Beta-Globin ratio was detected in 
responder patients, with a statistically significant difference between pre- and post-treatment 
(Student’s t-test, p<0.05 vs. baseline, 95% CI +0,85 to +1,85). Also the amount of both PI-PLCβ1 
splicing variants was assessed (Figure 16): PI-PLCβ1a significantly increased only in the late cycles 
(Student’s t-test, p<0.05 vs. baseline, 95% CI -0,63 to +0,05), while PI-PLCβ1b mRNA was not 
significantly induced by the therapy (Student’s t-test, p>0.05 vs. baseline, 95% CI -0,38 to +0,19). 
 
 
 
 
Figure 16. Gene expression of erythropoiesis markers and PI-PLCβ1 splicing variants in MDS responder patients 
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Lenalidomide induced PKCα localization within the nucleus, especially in cells not expressing high 
levels of PP2CA, whereas in the same cells PI-PLCβ1 seemed to be mainly cytoplasmic (Figure 17). 
 
 
 
 
 
 
Figure 17. Protein expression of inositide signalling in MDS responder patients 
 
4 Azacitidine and Lenalidomide effect on cell lines 
CELL CYCLE 
At first, 4 cell lines (HL60, MOLM-13, OCI-AML3 and THP-1) were treated for 24h with Azacitidine 
and/or Lenalidomide, and cell cycle was studied. Azacitidine alone induced a time-dependent 
increase of the Sub-G0/G1 phase, while Lenalidomide alone induced a time-dependent G0/G1 
arrest. The combination therapy showed both a cytotoxic effect, probably given by Azacitidine, 
and a G0/G1 arrest, that could be possibly linked to Lenalidomide (Figure 18).  
 
 
 
 
 
 
Figure 18. Cell cycle analysis of erythropoiesis in hematopoietic cell lines treated with Azacitidine and Lenalidomide 
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This double effect was particularly detectable in MOLM-13 cell line at 24h, where the cytotoxic 
effect of azacitidine was present, although not being the higher, and the Lenalidomide effect on 
inducing a G0/G1 arrest was significant (Figure 19). 
 
 
 
 
 
Figure 19. Cell cycle analysis of erythropoiesis in MOLM-13 cells treated with Azacitidine and Lenalidomide 
 
MOLECULAR ANALYSIS OF ERYTHROPOIESIS 
The same 4 cell lines (HL60, MOLM-13, OCI-AML3 and THP-1), treated with Azacitidine and 
Lenalidomide, were also tested for their expression of erythroid markers.  
At first, by flow cytometry analysis, we quantified the expression of CD71 and GPA, to test an early 
marker of erythropoiesis, i.e. CD71, and a later one, that is GPA (Figure 20). As CD71 was highly 
expressed in all cell lines and during all experimental conditions, we calculated the ratio between 
CD71 and GPA. In fact, an increased ratio is associated with an increased erythroid differentiation, 
in that the increased ratio is obtained when GPA increases and CD71 is constant or decreases. 
 
 
 
 
 
 
 
Figure 20. Flow cytometric analysis of erythropoiesis in hematopoietic cell lines treated with Azacitidine and Lenalidomide 
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The effect of the combination treatment was particularly significant in MOLM-13 cell line at 24h. 
Interestingly, MOLM-13 cells treated with Azacitidine alone for 24h showed a slight reduction of 
GPA (-1.94%), as compared to control, whereas Lenalidomide alone induced an increased GPA 
expression (+16.54), that was even higher in the combination treatment (+25.29%). In contrast, 
the slight differences on CD71 expression between all the experimental conditions were not 
statistically significant, although CD71 expression was always over 60% (Figure 21). 
 
 
 
 
 
Figure 21. Flow cytometric analysis of erythropoiesis in MOLM-13 cells treated with Azacitidine and Lenalidomide 
 
Erythropoiesis was also studied from another point of view, i.e. the quantification of Globin genes 
(Figures 22 and 23). We started from the assumption that Gamma-Globin is associated with an 
early erythropoiesis, while Beta-Globin is expressed at later stages. Interestingly, HL60 cells 
showed a high Gamma-Globin expression, whereas MOLM-13, OCI-AML3 and THP-1 cells 
displayed lower Gamma-Globin Levels. Remarkably, MOLM-13 cells treated for 24h with both 
Azacitidine and Lenalidomide showed an crease in Beta-Globin expression that was almost 
statistically significant (Figure 22). 
 
 
 
 
 
Figure 22. Gene expression analysis of Globin Genes in hematopoietic cell lines treated with Azacitidine and Lenalidomide 
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5. Azacitidine and Lenalidomide effect on MDS Patients: Mutations  
PATIENTS’ OUTCOME 
44 patients diagnosed with high-risk MDS were treated with a combination of Azacitidine and 
Lenalidomide (Table 4). The median follow-up was 15 months (range 2–54 months). 31 patients 
reached at least six cycles of therapy (T6) and were clinically evaluable for response. Moreover, 3 
patients showed a disease progression or hematologic improvement before T4 and were 
evaluated for response too, so that 34 cases were clinically evaluated for response. According to 
the revised IWG criteria (Cheson et al., 2006), the overall response rate (ORR) was 76.5% (26/34 
cases): CR (8/34, 23.5%), PR (1/34, 2.9%), marrow CR (mCR, 3/34, 8.8%), HI (8/34, 23.5%), HI+mCR 
(6/34, 17.6%), whereas 6/34 patients (17.6%) had a stable disease and 2/34 cases (5.9%) had a 
disease progression. Among the patients evaluated for response, 13 patients showed a first 
positive response within T4 and maintained it at T8 and after (good responders, GR); 9 patients 
showed a positive response within T4 and lost response at T8 (transient responders, TR); 4 
patients responded after T4 and maintained the response at T8 (late responders, LR); 8 patients 
never responded (non responders, NR). 
 
ILLUMINA GENE MUTATION ANALYSES 
Paired samples (pre- and post-treatment) were tested for mutations in genes that are recurrently 
mutated in myeloid malignancies. As the quality and quantity of DNA for each sample was critical, 
only 30/34 samples were tested at baseline and during the therapy: at T4 (n=2), T6 (n=2), T7 (n=2), 
T8 (n=19) and T10 (n=4), while 1 sample was tested at T4 and T8 (Table 5). 3/30 patients showed 
no mutations either at baseline or during therapy (they were tested at baseline and T6, T7, and 
T10), while all other patients (27/ 30) had at least one mutation (Table 3). In this latter group of 
patients, two genes (NRAS and CEBPA), in two patients, acquired specific mutations only during 
the therapy, while all other genes were mutated in all 27 patients both at baseline and during the 
treatment, showing different VAFs between baseline and treatment. Remarkably, all samples 
showing a statistically significant decreasing VAF during therapy for all variants, as compared to 
baseline (n=7), showed a favorable response to therapy (3 CR, 1 mCR, 1 HI+mCR, 1 PR, 1 HI). 
Conversely, none of the patients with SD (n=7) showed a major decreasing VAF during therapy for 
all variants, as compared to baseline. All other patients had similar VAFs between baseline and 
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therapy or showed a mixed behavior for all the variants identified (n=13). Collectively, the most 
frequently mutated genes were ASXL1 (14 cases=47%), TET2 (11 cases=37%), RUNX1 (8 
cases=27%) and SRSF2 (5 cases=17%). Interestingly, all patients showing the single SRSF2 mutation 
evolved to AML, while all patients without any somatic myeloid gene mutation had a favorable 
response (CR or HI) and did not progress into AML. 
 
Table 5. Gene mutation analysis by Illumina Cancer Myeloid Panel 
Patient  Gene Mutation type T0 T4 T6 T7 T8 T10 Clinical Outcome 
AML 
Evolution 
Time to 
AML 
Evolution 
Duration 
of 
Response 
1 TP53 c.376-1G>A - splice acceptor 18,10 38,75     SD YES 8 0 
2 DNMT3A P904L 15,68    16,63  CR YES 28 24 
3 
IDH2 R140Q 37,40    8,50  
mCR YES 36 10 SRSF2 P95L 51,9    10,60  
ASXL1 G646fs 32,00    9,90  
4 
ASXL1 G646 12,10     20,30 
HI YES 9 5 
RUNX1 G135D 11,70     21,70 
IDH1 R132C 0,32     21,20 
KIT E562* 2,40     5,90 
SRSF2 P95L 4,80     29,10 
5 SF3B1 R625C  14,48   18,60  SD YES 14 0 
6 
ASXL1 G644fs 10,60    5,70  PR YES 10 6 
RUNX1 D133fs 10,60    4,50  
7 
DNMT3A R882C 30,10    44,90  
SD YES 20 0 RUNX1 c.509-3C>G splice donor 14,5    43,30  
NRAS G12A 0    9,50  
8 ASXL1 L890F 7,12    13,39  CR NO 0 52 
9 
SF3B1 K700E 35,10    39,00  
HI+mCR NO 0 16 TET2 K306fs 27,80    38,20  
TET2 L1360fs 26,70    38,20  
10 
TET2 L264fs 25,40    30,50  
HI+mCR NO 0 47 TET2 I1873T 25,80    30,00  
PHF6 Y303* 42,00    46,90  
11 
TET2 K875fs 11,80     14,20 
HI YES 21 19 
TET2 Y1245fs 8,40     12,10 
SRSF2 p95H 9,80     5,40 
ASXL1 G646fs 10,10     14,10 
RUNX1 S322* 5,70     8,20 
12 ASXL1 G643fs 8,40    10,20  HI+mCR NO 0 6 
13 
DNMT3A R882C 19,80    21,70  
HI YES 25 9 
CBL c.1096-7A>G Spice site 14,30    19,90  
IDH2 R140Q 19,10    22,10  
CEBPA inframe TAD2 32,50    32,60  
14 ASXL1 G635fs 27,30    14,90  CR NO 0 50 
15 TP53 c.97-2A>C - splice acceptor 50,03    3,10  HI+mCR YES 15 11 
16 
DNMT3A R882S 16,20    5,00  CR NO 0 5 
IDH2 R140Q 18,10    3,60  
17 no somatic mutations        HI NO 0 18 
18 no somatic mutations        CR NO 0 50 
19 
TET2 G1288fs 10,45 0,32     HI NO 0 2 
TET2 R1451fs 19,13 14,52     
20 TET2 R1366H 50,10     48,80 SD YES 14 0 
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SRSF2 P95H 9,30     18,80 
SRSF2 H99N 5,20     9,40 
SRSF2 P96FS 5,00     7,60 
CEBPA H219fs 0     10,40 
CEBPA S193fs 0     10,10 
ASXL1 G646fs 13,00     15,10 
21 
NRAS G12V 18,72   15,57   
HI NO 0 3 
TET2 Q969fs 32,13   36,61   
TET2 E1401* 31,99   38,24   
SRSF2,MFSD11 P96fs 10,46   6,97   
SRSF2,MFSD11 P95H 20,69   20   
CEBPA P196dup 38,86   20,69   
RUNX1 R157fs 31,07   34,95   
22 
EZH2 S669R 44,90    32,10  
HI NO 0 5 
ASXL1 Y591fs 25,30    18,20  
RUNX1 c.497_508+3dupGAAGTGGAAGAGGTA Splice region 12,00    9,20  
ZRSR2 E65* 42,70    33,60  
ZRSR2 E74* 3,10    5,30  
23 
TET2 P1278Q 55,10    49,60  HI YES 11 7 
U2AF1 S34F 5,60    9,50  
24 
TET2 H650fs 35,83  33,74    
SD YES 9 0 
TET2 T1884A 38,51  37,21    
CBL G397V 38,99  36,36    
ASXL1 Q592* 37,62  35,75    
25 TP53 V73Argfs 12,31    1,74  CR YES 9 5 
26 
TET2 E846* 8,90    7,00  
mCR YES 13 3 SRSF2 P95H 7,80    6,20  
ASXL1 R693* 9,50    7,30  
27 
TP53 H179Q 1,90    5,79  
SD NO 0 0 ASXL1 G646fs 29,73    22,45  
U2AF1 Q157P 38,97    25,41  
28 
TET2 C1135Y 12,00    29,7  
HI+mCR NO 0 14 
TET2 Y1244fs 12,70    29,6  
ASXL1 A640fs 12,50    30,4  
RUNX1 N182fs 1,90    23,4  
29 no somatic mutations        CR NO 0 32 
30 
NRAS Y64C 1,14    6,26  
mCR NO 0 33 
TET2 P413fs 21,02    30,47  
TET2 Q1507* 51,44    42,60  
ASXL1 S1168fs 42,25    41,93  
RUNX1 P95T 41,99    43,73  
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INOSITIDE-SPECIFIC GENE MUTATION ANALYSES 
Paired samples (pre- and post-treatment) were also tested for other 31 genes, chosen among the 
inositide-specific signalling pathways (Table 6). Eight genes showed no baseline mutations and did 
not acquire any variant during the therapy (PRKCA, GSK3A, GSK3B, MZF1, MYB, NFKB1, CDKN2B, 
and SLC29A2), whereas SOD2 and HFE genes showed no mutations at baseline but acquired 
variants during the therapy. At baseline, 21/31 genes were mutated, with MAP2K3 gene showing 
95 variants. During the treatment, 19/31 genes acquired specific variants: MTOR, PIK3CA, PIK3R1, 
TNF, SOD2, MAP2K1, PLCG2, MAP2K3, MAP2K2, PLCB1 at T4, and PIK3CD, MTOR, AKT3, MAP3K1, 
PIK3R1, HFE, CDKN1A, SOD2, AKT1, PLCG2, MAP2K3, MAP2K2, PIK3R2, PLCB1, PLCG1, RPS6KA3 at 
T8 (Table 4).  
Table 6. Inositide-specific genes analyzed by Ion Torrent (Thermo Fisher). Red genes were not mutated at baseline nor acquired 
mutations during the treatment 
 
  Baseline T4 T8 
1 AKT1 PIK3CD PIK3CD PIK3CD 
2 AKT2 MTOR MTOR MTOR 
3 AKT3 MTOR|MTOR-AS1 MTOR|MTOR-AS1 MTOR|MTOR-AS1 
4 MAP2K1 AKT3 AKT3 AKT3 
5 MAP2K2 PIK3CA PIK3CA PIK3CA 
6 MAP2K3 MAP3K1 MAP3K1 MAP3K1 
7 MAP2K4 PIK3R1 PIK3R1 PIK3R1 
8 MAP3K1 CDKN1A CDKN1A CDKN1A 
9 PLCB1 AKT1 AKT1 AKT1 
10 PLCG1 AKT2 AKT2 AKT2 
11 PLCG2 PLCG2 PLCG2 PLCG2 
12 PIK3CA MAP2K4 MAP2K4 MAP2K4 
13 PIK3CD MAP2K3 MAP2K3 MAP2K3 
14 PIK3CG MAP2K2 MAP2K2 MAP2K2 
15 PIK3R1 PIK3R2 PIK3R2 PIK3R2 
16 PIK3R2 PIK3CG PIK3CG PIK3CG 
17 PRKCA PLCB1 PLCB1 PLCB1 
18 GSK3A PLCG1 PLCG1 PLCG1 
19 GSK3B CYP2D6|LOC101929829 CYP2D6|LOC101929829 CYP2D6|LOC101929829 
20 MTOR MAP2K1 MAP2K1  
21 MZF1 TNF TNF  
22 MYB RPS6KA3  RPS6KA3 
23 CDKN1A  SOD2 SOD2 
24 NFKB1   HFE 
25 CDKN2B   MAP2K1|SNAPC5 
26 TNF   CDKN2B-AS1|CDKN2B 
27 SOD2   PLCG1|MIR6871 
28 HFE   PLCG1|MIR6871 
29 SLC29A2    
30 RPS6KA3    
31 CYP2D6    
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As shown in Figure 23, in TR and NR patients, there was a significant increased VAF during therapy, 
as compared to baseline, with the acquisition of 233 specific variants at T8 in TR patients and 83 in 
NR patients. Interestingly, these two groups also showed a low number of variants at baseline: 4 in 
TR patients, affecting MAP2K2, CYPD26, and RPS6KA3 genes, and 8 in NR patients, affecting 
MAP3K1, PLCG2, MAP2K3, PLCB1 and RPS6KA3 genes. Therefore, VAF increased by 58 times in TR 
patients and 10 times in NR patients, as compared to baseline. 
 
 
 
 
 
 
 
 
Figure 23. Inositide-specific mutated variants in MDS patients at baseline, at the 4th cycle (T4) and at the 8th cycle (T8) of Azacitidine 
and Lenalidomide therapy. Venn diagram showing the global number of mutated variants in: A. all patients analyzed, B. Good 
Responders, C. Transient Responders, D. Non Responders 
 
IDENTIFICATION OF A 3-GENE CLUSTER ASSOCIATED WITH LOSS OF RESPONSE 
The SIFT score(Ng and Henikoff, 2003) was used to further analyze the mutation profile: 11 genes 
(6 only at T8 and 5 both at T4 and T8) were mutated in TR patients, while 7 genes (6 only at T8 and 
1 only at T4) were mutated in NR patients (Figure 24). On the contrary, in all patients responding 
to the treatment at T8 (including both GR and LR), only 3 genes (SOD2, PLCG2, PIK3CD) acquired 
specific common mutations at T4 and T8 (Figure 24). Interestingly, in both TR and NR patients, 
there was a common specific cluster of 6 mutated genes (MAP2K1, PIK3CD, RPS6KA3, AKT3, 
PIK3CG, PLCG2), detected as 88 variants in TR patients and 34 variants in NR patients (Figure 24).  
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Figure 24. Inositide-Specific mutated genes according to the SIFT score in MDS patients at baseline, at the 4th cycle (T4) and at the 
8th cycle (T8) of Azacitidine and Lenalidomide therapy. Venn diagram showing the global number of mutated genes, divided 
according to the SIFT score, in: A. all patients analyzed, B. Good Responders, C. Transient Responders, D. Non Responders. The 
bottom part of the Figure shows the genes acquiring specific mutations during the therapy in: E. all patients analyzed (common T4 
and T8, n = 1), F. GR patients (common T4 and T8, n = 3), G. TR patients (common T4 and T8, n = 5; T8 only, n = 6), H. NR patients (T8 
only, n = 6), clustered according to the SIFT score: gray squares indicate no mutation, green to red squares indicate a lower to higher 
probability of impaired protein function due to mutation 
 
A depth analysis of these variants not only showed that 3 genes (PIK3CD, AKT3, and PLCG2) were 
commonly altered at T8 in both these two groups but, more interestingly, the same 3 point 
mutations were acquired: D133E in PIK3CD gene, D280G in AKT3 gene, and Q548R in PLCG2 gene 
(Figure 25). Interestingly, the sequence analysis of these point mutations revealed that the 
mutation affecting AKT3 was included in the catalytic domain of AKT3, while PLCG2 mutation was 
located within the N-terminal Src homology 2 (N-SH2) – phosphotyrosine binding pocket domain 
(Follo et al., 2019). 
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Figure 25. Common point mutations affecting 3 inositide-specific genes in MDS patients early losing response and never responding 
to azacitidine and lenalidomide therapy. Domain structure of A. PIK3CD, B. AKT3, and C. PLCG2 proteins, along with the sequence 
domains affected by gene mutations: the mutated amino acids are highlighted in pink. Amino acids already known to be implicated 
in protein function are highlighted in yellow. Abbreviations: BD: binding domain; C2: calcium-binding domain; HD: hydrophobic 
regulatory domain; PH, Pleckstrin-homology domain; X-Box: phosphatidylinositol-specific phospholipase C X domain; SH2: Src 
homology 2 domain; SH3: Src homology 3 domain; Y-Box: phosphatidylinositol-specific phospholipase C Y domain 
 
SURVIVAL ANALYSES 
As reported in Figure 26, the association between SRSF2 mutations and OS was close to significant: 
30 vs 12 months with 95% CI +2.15 to +2.84, p = 0.05; HR = 0.25 with 95% CI +0.06 to +1.04. Also 
the association between SRSF2 mutations and LFS was close to significant: 28 vs 9 months with 
95% CI +2.76 to +3.45, p = 0.05; HR = 0.24 with 95% CI +0.06 to +1.02. On the contrary, SRSF2 
mutations were not significantly associated with duration of response: 28 vs 14.5 months with 
95% CI +1.64 to +2.21; p = 0.11; HR = 0.27 with 95% CI +0.06 to +1.35. On the other hand, the 
presence of our inositide-mutated 3-gene cluster was significantly associated with a shorter OS (35 
vs 15 months with 95% CI +1.84 to +2.81, p = 0.046; HR = 0.24 with 95% CI +0.09 to +0.64), a 
shorter LFS (28 vs 13.5 months with 95% CI +1.58 to +2.56, p = 0.0011; HR = 0.19 with 95% CI 
+0.07 to +0.52) and a shorter duration of response (16 vs 5 months with 95% CI +2.78 to +3.62, p = 
0.0012; HR = 0.09 with 95% CI +0.02 to +0.38). 
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Figure 26. Kaplan–Meier estimates of overall survival, leukemia-free survival, and duration of response in MDS patients treated with 
azacitidine and lenalidomide. a Patients are stratified according to the presence of SRSF2 mutation (SRSF2) or the absence of SRSF2 
mutation (NO MUT). b Patients are stratified according to the presence of our 3-inositide gene mutation (CLUSTER) or the absence 
of our 3-inositide gene mutation (NO MUT). *p < 0.05 CLUSTER vs NO MUT 
 
6. Azacitidine and Lenalidomide effect on MDS patients: miRs 
The differential expression of miRs was evaluated comparing miR profiles at baseline and during 
the therapy, starting from the miR profiling at T0 vs T4, to determine a first relationship between 
therapy and the first clinical response. Patients were retrospectively analyzed, thus divided into 
responders and non responders at T4. 
The miRs that were significantly expressed (up- or down-regulated) in the bioinformatic analysis 
were those with a P-Value less than 0.05 (95% significance) and a logFC value greater than 0.5 (the 
higher the absolute value of the logFC and the smaller the P-Value, the more significant is the 
change in the expression of miRs). Therefore, a logFC with a value greater than zero is indicative of 
an up-regulation of the miR, while a logFC with a value less than zero is associated with a down-
regulation of the miR.  
From the data reported in Tables 7 and 8, derived from the paired analysis of T0 vs T4 in 
responder patients and non responder patients, it is clear that there were miR groups (clusters) 
expressed with a statistical difference during treatment. Of these, fourteen miRs were up-
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regulated during the therapy and twenty-eight miRs were down-regulated at T4, as compared to 
T0 (baseline).  
 
miRNA ID logFC P-Value Locus 
U74 1,08 0,04043 chr1:173836812-173836883 (-) 
U101 1,05 0,03260 chr6:133136446-133136518 (+) 
hsa-miR-146a-5p 0,91 0,02175 chr5:159912379-159912400 (+) 
U49A 0,88 0,03010 chr17:16343350-16343420 (+) 
U49A 0,80 0,04978 chr17:16343350-16343420 (+) 
U31 0,79 0,00219 chr11:62620797-62620867 (-) 
hsa-miR-29a-3p 0,79 0,02445 chr7:130561507-130561528 (-) 
U51 0,73 0,01034 chr2:207026605-207026674 (+) 
hsa-miR-143-3p 0,72 0,01159 chr5:148808541-148808561 (+) 
hsa-miR-15a-5p 0,64 0,03252 chr13:50623303-50623324 (-) 
U37 0,60 0,04461 chr19:3982505-3982570 (-) 
SNORD121B 0,58 0,03665 chr9:33934295-33934373 (-) 
U31 0,58 0,00563 chr11:62620797-62620867 (-) 
hsa-miR-30d-5p 0,50 0,03000 chr8:135817162-135817183 (-) 
Table 7. Bioinformatics analysis of up-regulated miRs (paired analysis T0 vs T4) 
 
miRNA ID logFC P-Value Locus 
hsa-miR-1273g-3p -2,33 0,00825 chr1:53406042-53406062 (+) 
U58B -1,53 0,01224 chr18:47018034-47018099 (-) 
hsa-miR-4492 -1,52 0,02238 chr11:118781474-118781490 (+) 
U76 -1,50 0,00998 chr1:173835773-173835852 (-) 
ACA44 -1,39 0,01597 chr1:28906893-28907024 (-) 
ENSG00000252840 -1,39 0,01597 chr1:151500307-151500414 (-) 
U55 -1,38 0,02517 chr1:45241537-45241610 (+) 
U57 -1,18 0,03442 chr20:2637585-2637656 (+) 
hsa-miR-320b -1,16 0,02857 chr1:117214409-117214430 (+)/ 
  hsa-miR-4463 -1,07 0,04963 chr6:76138162-76138178 (+) 
hsa-miR-4508 -1,05 0,04954 chr15:23807254-23807270 (-) 
U33 -1,04 0,02600 chr19:49993874-49993956 (+) 
hsa-miR-4467 -0,99 0,03569 chr7:102111919-102111940 (+) 
U48 -0,96 0,03423 chr6:31803040-31803103 (+) 
U52 -0,96 0,01498 chr6:31804853-31804916 (+) 
hsa-miR-4433b-3p -0,95 0,02949 chr2:64567903-64567923 (-) 
hsa-miR-6803-5p -0,94 0,04965 chr19:55756592-55756613 (-) 
U32A -0,90 0,04095 chr19:49993225-49993301 (+) 
U68 -0,84 0,03071 chr19:17973397-17973529 (+) 
U105B -0,83 0,04960 chr19:10220433-10220511 (+) 
ENSG00000199411 -0,81 0,04032 chr9:139988797-139988882 (+) 
hsa-miR-1207-5p -0,75 0,02661 chr8:129061405-129061425 (+) 
HBII-276 -0,72 0,01882 chr8:67834709-67834784 (-) 
HBII-115 -0,70 0,04579 chr19:48259110-48259219 (+) 
hsa-miR-4649-5p -0,68 0,04950 chr7:44150450-44150473 (+) 
hsa-miR-6794-5p -0,67 0,03539 chr19:12963079-12963098 (+) 
U38A -0,52 0,03889 chr1:45243514-45243584 (+) 
U3-2B -0,50 0,00621 chr17:18967233-18967449 (-) 
 
Table 8. Bioinformatics analysis of down-regulated miRs (paired analysis T0 vs T4) 
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Interestingly, a preliminary analysis of the molecular targets of the clustered miRs showed that 
inositide-signalling molecules could be involved, as among the predicted or validated targets of 
the miRs were inositide players, including the same three genes that acquired mutations during 
Azacitidine and Lenalidomide therapy (Figure 27).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. For miR profiling, responders vs non responder patients at the 4th cycle showed 42 miRs with a statistically significant 
differential expression, with 14 up- and 28 down-regulated miRs, whose predicted targets are often inositide-specific molecules and, 
in some cases, the same three genes that acquired specific mutations during loss of response to therapy. 
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Discussion  
Nuclear inositide signalling pathways are deregulated in MDS, and nuclear PI-PLCβ1 plays 
important roles in the regulation of hematopoietic differentiation, both at a myeloid and an 
erythroid level. Indeed, the epigenetic regulation of PI-PLCβ1, which is linked to the demethylating 
effect of Azacitidine therapy, has been associated with a specific induction of the myeloid 
differentiation of MDS cells, via the recruitment of the MZF-1 transcription factor (Yang et al., 
2013). On the other hand, PI-PLCβ1 is also a negative regulator of the erythroid differentiation, 
possibly through the PI-PLCβ1/PKCα signalling pathway (Bavelloni et al., 2014). 
Azacitidine alone is currently used in higher-risk MDS, whereas Lenalidomide is mainly used in 
del(5q) MDS patients, who show a favourable outcome in the vast majority of cases. However, 
some patients can be or become refractory to these single approaches, that is why a combination 
therapy based on Azacitidine and Lenalidomide administration is being tested, with positive 
clinical results.  
However, the molecular mechanisms underlying the effect of this combination therapy, especially 
in non-del(5q) patients, are still unclear. That is why in this study we analyzed the molecular 
effects of Azacitidine and Lenalidomide combination on the nuclear inositide-dependent 
pathways, mainly focusing on PI-PLCβ1. 
At first, we deeply investigated the molecular effect of Lenalidomide therapy in hematopoietic cell 
lines and MDS patients, with particular reference to inositide signalling pathways. We tested both 
del(5q) and non-del(5q) cells, in order to better understand the effect of Lenalidomide on both 
clones.  
In particular, we studied the effect of Lenalidomide on hematopoietic cell lines, using Namalwa 
CSN.70 cells, showing a del(5q) karyotype, and U937 cells, showing a normal 5q chromosome. As 
for the cell cycle analyses, only Namalwa CSN.70 cells (i.e. del(5q) cells) showed a Lenalidomide-
dependent arrest of cell cycle in the G0/G1 phase, which also corresponded to an increase of p21, 
p27 and a slight decreased expression of cyclin D3 and cyclin E. On the contrary, in non-del(5q) 
cells (i.e. U937 cells), Lenalidomide did not significantly affect cell cycle. Therefore, our data show 
that Lenalidomide can induce a selective arrest of cell cycle in G0/G1 phase of del(5q) cells, thus 
slowing the rate proliferation of this cell clone. On the contrary, the activation of p21, p27 and 
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cyclins in non-del(5q) cells results in a normal cell proliferation. Therefore, Lenalidomide seems to 
specifically slow the proliferation of the del(5q) clone, possibly promoting instead its erythroid 
differentiation.  
Indeed, Namalwa CSN.70 cells showed a decrease of Gamma/Beta-Globin ratio, an increase of 
GPA and a reduction of CD71 erythroid-specific surface markers during Lenalidomide treatment, 
confirming the specific induction of erythropoiesis in the del(5q) cells. On the contrary, U937 cells 
treated with Lenalidomide showed a higher amount not only of Globin genes, but also of both GPA 
and CD71 markers, thus indicating that in these non-del(5q) cells the erythroid differentiation was 
not specifically induced, although the almost constant amount of PI-PLCβ1b during Lenalidomide 
treatment in these non-del(5q) cells also showed that the erythropoiesis was not specifically 
inhibited. In fact, PI-PLCβ1a splicing variant is generally mainly localized in the cytoplasm, and is 
not directly associated with inhibition of erythroid differentiation, while nuclear PI-PLCβ1 (i.e. PI-
PLCβ1b splicing variant) is a negative regulator of erythropoiesis. Our data on cell lines showed 
that Lenalidomide specifically induces the expression of PI-PLCβ1 in the cytoplasm of Namalwa 
CSN.70 (i.e. del(5q) cells), where also a nuclear translocation of PKCα, which can be associated 
with erythropoiesis, is detected.  
The molecular erythroid effect of Lenalidomide was also tested in MDS cells, by analyzing the PI-
PLCβ1/PKCα signalling, as well as the expression of GPA, CD71 or the Globin genes. In our MDS 
case series, 5/16 patients early discontinued Lenalidomide, and for these patients neither a clinical 
assessment of Lenalidomide effect, nor a molecular analysis, were possible. Among the remaining 
patients, 10 subjects responded to Lenalidomide, whereas the non responder patient showed a 
stable disease after treatment. At a molecular level, only responder patients showed an activation 
of erythropoiesis, in that the Gamma/Beta-Globin ratio decreased, as compared with baseline. 
Moreover, these subjects displayed a specific increase of PI-PLCβ1a, but not PI-PLCβ1b mRNA, 
especially in the last cycles of therapy. As for PI-PLCβ1/PKCα signalling, we performed a double 
immunostaining with PP2CA and PI-PLCβ1 or PKCα on MDS mononuclear cells: as PP2CA gene is 
localized in the 5q chromosome, cells showing both proteins were considered as non-del(5q)cells, 
whereas cells with a low amount of PP2CA were del(5q) cells. Surprisingly, we detected a distinct 
behaviour between del(5q) and non-del(5q) MDS cells from responder patients in that, during 
Lenalidomide therapy, PI-PLCβ1 seemed to be localized mainly in the cytoplasm of the del(5q) cells 
while, in the same subpopulation, PKCα translocated to the nucleus.  
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As previously mentioned, some patients can be refractory to Azacitidine or Lenalidomide alone. 
Therefore, the combination of Azacitidine and Lenalidomide has been clinically investigated. 
However, the molecular effect of this combination therapy is still unknown, above all in terms of 
mutation profiling, although the extent of genetic rearrangements has been associated with 
outcome and response to treatment (Ganster et al., 2015). Moreover, as a reliable clinical 
evaluation of the combination therapy effect is possible only after several cycles of therapy, the 
identification of predictive molecular markers of response/resistance would be very helpful, above 
all because the persistence of mutated subclones can influence the response to epigenetic therapy 
(Uy et al., 2017).  
In this study, the molecular mechanisms underlying Azacitidine and Lenalidomide therapy were 
investigated in both cell lines and MDS patients.  
At first, four types of hematopoietic cells were tested, finding out that Azacitidine and 
Lenalidomide treatment can induce an increase of the Sub-G0/G1 phase, as well as a G0/G1 arrest. 
Moreover, the combination therapy was also able to specifically induce erythropoiesis, as cells 
showed an increase in GPA expression and, especially in MOLM-13 cells, a decreased Gamma/Beta 
Globin ratio, that is associated with erythroid induction. All in all, these results hint at an additive 
effect of the cytotoxic effect of Azacitidine alone and the capability of Lenalidomide to induce cell 
cycle arrest and erythroid differentiation. Possibly, in a mixed cell population, the combination 
therapy would selectively induce apoptosis and cell cycle arrest in del(5q) cells, favouring the 
erythroid differentiation and restoring a normal hematopoiesis. 
In this study we also focused on the molecular effect on Azacitidine and Lenalidomide on the 
mutation profile of cancer myeloid genes (i.e., ASXL1, RUNX1, TET2, IDH1/2) as well as a selection 
of inositide-related genes, known to be involved in survival pathways (i.e., PI3K/Akt/mTOR, 
RAS/MAPK), hematopoietic differentiation (i.e., PKCα, PI-PLCγ2) [(Poli et al., 2017b), cell cycle (i.e., 
CDKN2B, PKCC α) (Poli et al., 2014a) or drug metabolism (i.e., RPS6KA3,SOD2, CYP2D6, SLC29A2).  
In particular, we analyzed the mutation profile of MDS samples at baseline and during the 
combination therapy (possibly both at T4 and T8) and correlated it with clinical outcome, OS, LFS, 
and response to therapy.  
In our patient cohort, three patients did not show any myeloid gene mutation neither at baseline 
nor during therapy: they all had a favorable response (CR or HI) and did not progress into AML. In 
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contrast, all remaining patients showed at least one myeloid-related mutation at baseline and 
maintained it during the therapy, although showing different VAFs according to the clinical 
response.  
All samples showing a decreasing VAF during therapy, as compared to baseline levels, had a 
favorable response (mainly CR, mCR or PR), while none of the non responders showed a 
decreasing VAF. Collectively, the most frequently mutated cancer myeloid genes were ASXL1 
(47%), TET2 (37%), RUNX1 (27%) and SRSF2 (17%). Interestingly, all patients showing the single 
SRSF2 mutation evolved to AML, although the association between the presence of SRSF2 
mutations and the LFS was close to significant (p = 0.05). This could be due to the low number of 
cases analyzed so far, but is still indicative of a negative correlation that needs to be investigated, 
also in the light of recent data from AML patients showing that SRSF2 persisting mutations are 
associated with a higher cumulative incidence of relapse(Rothenberg-Thurley et al., 2018).  
As for the inositide-specific genes, 8 genes never showed mutations, neither at baseline nor during 
therapy: PRKCA, GSK3A, GSK3B, MZF1, MYB, NFKB1, CDKN2B, and SLC29A. Interestingly, this 
cluster included genes involved in inositide metabolism (PRKCA), cell cycle regulation (CDKN2B) 
and myeloid differentiation (MZF1 and MYB). On the other hand, 21/31 genes showed mutations 
at baseline and during the treatment, and 19/31 genes acquired specific variants.  
Collectively, there was a significant increased VAF during therapy in TR or NR patients, that 
showed an increased number of acquired mutations at T8. Moreover, these two groups also 
showed the lowest number of variants at baseline: 4 in TR patients, affecting MAP2K2, CYPD26, 
and RPS6KA3 genes, and 8 in NR patients, affecting MAP3K1, PLCG2, MAP2K3, PLCB1, and 
RPS6KA3 genes.  
A deeper analysis of the inositide-specific mutation profile, performed by using the SIFT score(Ng 
and Henikoff, 2003), that predicts the effect of a point mutation on the protein function, revealed 
a small cluster of 6 genes commonly mutated only in TR and NR patients: MAP2K1, PIK3CD, 
RPS6KA3, AKT3, PIK3CG, and PLCG2. More interestingly, 3 of these genes (PIK3CD, AKT3, and 
PLCG2) acquired the same 3 point mutations: D133E in PIK3CD gene, D280G in AKT3 gene, and 
Q548R in PLCG2 gene.  
The analysis of the aminoacid characteristics, as well as the examination of the protein sequence, 
revealed that the D280G and Q548R mutations could affect aminoacid polarization (thus possibly 
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protein structure and function), in that D is negatively charged, G and Q have no charge and R is 
positively charged. Moreover, both AKT3 and PLCG2 point mutations localize within important 
protein domains: the catalytic domain of AKT3 and the N-terminal Src homology 2 (N-SH2) - 
phosphotyrosine binding pocket domain of PLCG2. Interestingly, the aminoacid changes that we 
observed are included in these domains but affect aminoacids not yet known to be important for 
protein function. That is why a functional analysis of this aminoacid change could disclose the 
meaning of the identified point mutations. In contrast, the aminoacid change affecting PIK3CD is 
located at the N-terminal and does not affect any known domain.  
Remarkably, the presence of our inositide-mutated 3-gene cluster (PI3KCD, AKT3 and PLCG2) was 
significantly associated with a shorter OS, a shorter LFS and a shorter duration of response. This 
could be important, as the detection of these 3 point mutations could predict the unfavorable 
effect of Azacitidine and Lenalidomide combination therapy in MDS patients. Furthermore, as 
PI3KCD and AKT3 genes are actively involved in cell proliferation, it is likely that the acquisition of 
these specific point mutations in MDS not responding to therapy could give a proliferative 
advantage to mutated cells. On the other hand, as PLCG2 has been associated with myeloid 
differentiation, it is also likely that the acquisition of our specific point mutation in non responder 
MDS patients could result in an impaired hematopoietic differentiation that leads to a stable 
disease or AML progression. 
Although the mutation profile was not entirely capable of predicting the clinical effect of the 
epigenetic therapy, the presence of specific three point mutations affecting three important 
inositide genes (PI3KCD, AKT3 and PLCG2) was correlated to and anticipated a negative clinical 
outcome. Indeed, all of the MDS patients included in this study that acquired the mutated cluster 
were also refractory to Azacitidine and Lenalidomide therapy at T8. Although this is a preliminary 
analysis, performed on a relatively small number of cases, the statistically significant association 
between this cluster and a shorter OS, LFS and duration of response pave the way to larger 
studies.  
To our knowledge, this is the first time that a systematic mutation analysis of inositide-related 
genes during Azacitidine and Lenalidomide therapy in MDS has been performed. More 
importantly, our findings indicate that a specific mutated 3-gene cluster is associated with early 
loss of response or refractoriness. Given the involvement of nuclear inositides in cell cycle and in 
hematopoietic differentiation, and on the basis of our results, we feel that further investigating 
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the effect of these point mutations on protein function could be important to understand the 
basic and translational implications of these mutations, to find alternative strategies aiming to 
activate specific signalling pathways to induce cancer cell apoptosis and/or normal myeloid 
differentiation in MDS. 
Finally, the miR results, although from preliminary experiments, point out at the relevant role that 
inositide pathways could play also in miR regulation. In fact, Azacitidine and Lenalidomide 
combination therapy altered the expression of several miRs, above all of those involved in the 
regulation of cell proliferation, differentiation and apoptosis. Moreover, the differential miR 
expression was detectable even from T4 in responder patients, as compared to non responders.  
Although these are preliminary data that need to be validated by quantifying the miR gene 
expression or by performing functional analyses on the downstream targets, these findings could 
still be important to better understand MDS pathogenesis and pave the way to new therapeutic 
approaches for MDS. 
All in all, our data confirm the results of previous studies (Mongiorgi et al., 2016b; Poli et al., 
2017b), in that also in this study nuclear inositides, and particularly PI-PLCβ1, were associated with 
MDS. Moreover, our results show that Azacitidine and Lenalidomide therapy in high-risk MDS 
patients can induce a favourable clinical response, and that the molecular mutation profiling of 
inositide genes or a specific mini-cluster of differentially expressed miRs, targeting inositide 
signaling molecules, can be associated with the clinical response, either positive or negative, thus 
possibly predicting the effect of the therapy. 
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